Does patient cost sharing for HCV drugs make sense?
USC Schaeffer Center, 635 Downey Way, Verna & Peter Dauterive Hall (VPD), Ste 210, Los Angeles, CA 90089-3333. E-mail: dlakdawa@healthpolicy.usc.edu.
Darius N
DN
Lakdawalla
Mark T
MT
Linthicum
Jacqueline
J
Vanderpuye-Orgle
D000998:Antiviral Agents / Q000191:economics* / Q000600:supply & distribution / Q000627:therapeutic use; D017047:Cost Sharing; D003362:Cost-Benefit Analysis; D006297:Health Services Accessibility / Q000191:economics* / Q000592:standards; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D007348:Insurance, Health / Q000191:economics* / Q000592:standards; D016903:Drug Monitoring
D000998:Antiviral Agents